Cargando…

The prevalence of Mycoplasma genitalium (MG) and Trichomonas vaginalis (TV) at testing centers in Belgium, Germany, Spain, and the UK using the cobas TV/MG molecular assay

Mycoplasma genitalium (MG) and Trichomonas vaginalis (TV) can lead to long-term sequelae in males and females; however, global prevalence data vary between geographical regions, as these sexually transmitted infections are not included in routine screening. The objective of this study was to use the...

Descripción completa

Detalles Bibliográficos
Autores principales: Perry, Michael D., Jones, Sophie, Bertram, Alexander, de Salazar, Adolfo, Barrientos-Durán, Antonio, Schiettekatte, Gilberte, Lewinski, Michael, Arcenas, Rodney, Hansra, Avneet, Njoya, Merlin, García, Federico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9816248/
https://www.ncbi.nlm.nih.gov/pubmed/36369413
http://dx.doi.org/10.1007/s10096-022-04521-5
_version_ 1784864490577199104
author Perry, Michael D.
Jones, Sophie
Bertram, Alexander
de Salazar, Adolfo
Barrientos-Durán, Antonio
Schiettekatte, Gilberte
Lewinski, Michael
Arcenas, Rodney
Hansra, Avneet
Njoya, Merlin
García, Federico
author_facet Perry, Michael D.
Jones, Sophie
Bertram, Alexander
de Salazar, Adolfo
Barrientos-Durán, Antonio
Schiettekatte, Gilberte
Lewinski, Michael
Arcenas, Rodney
Hansra, Avneet
Njoya, Merlin
García, Federico
author_sort Perry, Michael D.
collection PubMed
description Mycoplasma genitalium (MG) and Trichomonas vaginalis (TV) can lead to long-term sequelae in males and females; however, global prevalence data vary between geographical regions, as these sexually transmitted infections are not included in routine screening. The objective of this study was to use the cobas(®) TV/MG assay to assess the point prevalence of TV and MG in specimens from men and women over a broad European geographical area. Urine, vaginal, endocervical, and rectal samples were collected from patients aged ≥ 18 years receiving Chlamydia trachomatis (CT) and/or Neisseria gonorrhoeae (NG) screening as per local standard of care at sites in Belgium, Germany, Spain, and the UK (Wales). Remnant samples were assessed using the cobas TV/MG assay. Analysis of 2795 samples showed that MG prevalence varied slightly across female sample types (range: 1.7–5.8%; p = 0.0042). MG prevalence was higher in male rectal samples (12.5%) than in male urine samples (3.9%; p < 0.0001). TV prevalence was low in male (0.8%; 12/1535) and female (1.3%; 16/1260) samples across all sites. Co-infection of TV/MG with CT or NG was 10.0% (19/190) and 9.6% (7/73), respectively, in both male and female samples. MG and TV prevalence rates were comparable to the published literature in Europe. MG prevalence was highest in male rectal samples; as rectal testing is an off-label use of the cobas TV/MG assay, the clinical utility of this assay for rectal testing should be further investigated. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10096-022-04521-5.
format Online
Article
Text
id pubmed-9816248
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-98162482023-01-07 The prevalence of Mycoplasma genitalium (MG) and Trichomonas vaginalis (TV) at testing centers in Belgium, Germany, Spain, and the UK using the cobas TV/MG molecular assay Perry, Michael D. Jones, Sophie Bertram, Alexander de Salazar, Adolfo Barrientos-Durán, Antonio Schiettekatte, Gilberte Lewinski, Michael Arcenas, Rodney Hansra, Avneet Njoya, Merlin García, Federico Eur J Clin Microbiol Infect Dis Original Article Mycoplasma genitalium (MG) and Trichomonas vaginalis (TV) can lead to long-term sequelae in males and females; however, global prevalence data vary between geographical regions, as these sexually transmitted infections are not included in routine screening. The objective of this study was to use the cobas(®) TV/MG assay to assess the point prevalence of TV and MG in specimens from men and women over a broad European geographical area. Urine, vaginal, endocervical, and rectal samples were collected from patients aged ≥ 18 years receiving Chlamydia trachomatis (CT) and/or Neisseria gonorrhoeae (NG) screening as per local standard of care at sites in Belgium, Germany, Spain, and the UK (Wales). Remnant samples were assessed using the cobas TV/MG assay. Analysis of 2795 samples showed that MG prevalence varied slightly across female sample types (range: 1.7–5.8%; p = 0.0042). MG prevalence was higher in male rectal samples (12.5%) than in male urine samples (3.9%; p < 0.0001). TV prevalence was low in male (0.8%; 12/1535) and female (1.3%; 16/1260) samples across all sites. Co-infection of TV/MG with CT or NG was 10.0% (19/190) and 9.6% (7/73), respectively, in both male and female samples. MG and TV prevalence rates were comparable to the published literature in Europe. MG prevalence was highest in male rectal samples; as rectal testing is an off-label use of the cobas TV/MG assay, the clinical utility of this assay for rectal testing should be further investigated. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10096-022-04521-5. Springer Berlin Heidelberg 2022-11-11 2023 /pmc/articles/PMC9816248/ /pubmed/36369413 http://dx.doi.org/10.1007/s10096-022-04521-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Perry, Michael D.
Jones, Sophie
Bertram, Alexander
de Salazar, Adolfo
Barrientos-Durán, Antonio
Schiettekatte, Gilberte
Lewinski, Michael
Arcenas, Rodney
Hansra, Avneet
Njoya, Merlin
García, Federico
The prevalence of Mycoplasma genitalium (MG) and Trichomonas vaginalis (TV) at testing centers in Belgium, Germany, Spain, and the UK using the cobas TV/MG molecular assay
title The prevalence of Mycoplasma genitalium (MG) and Trichomonas vaginalis (TV) at testing centers in Belgium, Germany, Spain, and the UK using the cobas TV/MG molecular assay
title_full The prevalence of Mycoplasma genitalium (MG) and Trichomonas vaginalis (TV) at testing centers in Belgium, Germany, Spain, and the UK using the cobas TV/MG molecular assay
title_fullStr The prevalence of Mycoplasma genitalium (MG) and Trichomonas vaginalis (TV) at testing centers in Belgium, Germany, Spain, and the UK using the cobas TV/MG molecular assay
title_full_unstemmed The prevalence of Mycoplasma genitalium (MG) and Trichomonas vaginalis (TV) at testing centers in Belgium, Germany, Spain, and the UK using the cobas TV/MG molecular assay
title_short The prevalence of Mycoplasma genitalium (MG) and Trichomonas vaginalis (TV) at testing centers in Belgium, Germany, Spain, and the UK using the cobas TV/MG molecular assay
title_sort prevalence of mycoplasma genitalium (mg) and trichomonas vaginalis (tv) at testing centers in belgium, germany, spain, and the uk using the cobas tv/mg molecular assay
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9816248/
https://www.ncbi.nlm.nih.gov/pubmed/36369413
http://dx.doi.org/10.1007/s10096-022-04521-5
work_keys_str_mv AT perrymichaeld theprevalenceofmycoplasmagenitaliummgandtrichomonasvaginalistvattestingcentersinbelgiumgermanyspainandtheukusingthecobastvmgmolecularassay
AT jonessophie theprevalenceofmycoplasmagenitaliummgandtrichomonasvaginalistvattestingcentersinbelgiumgermanyspainandtheukusingthecobastvmgmolecularassay
AT bertramalexander theprevalenceofmycoplasmagenitaliummgandtrichomonasvaginalistvattestingcentersinbelgiumgermanyspainandtheukusingthecobastvmgmolecularassay
AT desalazaradolfo theprevalenceofmycoplasmagenitaliummgandtrichomonasvaginalistvattestingcentersinbelgiumgermanyspainandtheukusingthecobastvmgmolecularassay
AT barrientosduranantonio theprevalenceofmycoplasmagenitaliummgandtrichomonasvaginalistvattestingcentersinbelgiumgermanyspainandtheukusingthecobastvmgmolecularassay
AT schiettekattegilberte theprevalenceofmycoplasmagenitaliummgandtrichomonasvaginalistvattestingcentersinbelgiumgermanyspainandtheukusingthecobastvmgmolecularassay
AT lewinskimichael theprevalenceofmycoplasmagenitaliummgandtrichomonasvaginalistvattestingcentersinbelgiumgermanyspainandtheukusingthecobastvmgmolecularassay
AT arcenasrodney theprevalenceofmycoplasmagenitaliummgandtrichomonasvaginalistvattestingcentersinbelgiumgermanyspainandtheukusingthecobastvmgmolecularassay
AT hansraavneet theprevalenceofmycoplasmagenitaliummgandtrichomonasvaginalistvattestingcentersinbelgiumgermanyspainandtheukusingthecobastvmgmolecularassay
AT njoyamerlin theprevalenceofmycoplasmagenitaliummgandtrichomonasvaginalistvattestingcentersinbelgiumgermanyspainandtheukusingthecobastvmgmolecularassay
AT garciafederico theprevalenceofmycoplasmagenitaliummgandtrichomonasvaginalistvattestingcentersinbelgiumgermanyspainandtheukusingthecobastvmgmolecularassay
AT perrymichaeld prevalenceofmycoplasmagenitaliummgandtrichomonasvaginalistvattestingcentersinbelgiumgermanyspainandtheukusingthecobastvmgmolecularassay
AT jonessophie prevalenceofmycoplasmagenitaliummgandtrichomonasvaginalistvattestingcentersinbelgiumgermanyspainandtheukusingthecobastvmgmolecularassay
AT bertramalexander prevalenceofmycoplasmagenitaliummgandtrichomonasvaginalistvattestingcentersinbelgiumgermanyspainandtheukusingthecobastvmgmolecularassay
AT desalazaradolfo prevalenceofmycoplasmagenitaliummgandtrichomonasvaginalistvattestingcentersinbelgiumgermanyspainandtheukusingthecobastvmgmolecularassay
AT barrientosduranantonio prevalenceofmycoplasmagenitaliummgandtrichomonasvaginalistvattestingcentersinbelgiumgermanyspainandtheukusingthecobastvmgmolecularassay
AT schiettekattegilberte prevalenceofmycoplasmagenitaliummgandtrichomonasvaginalistvattestingcentersinbelgiumgermanyspainandtheukusingthecobastvmgmolecularassay
AT lewinskimichael prevalenceofmycoplasmagenitaliummgandtrichomonasvaginalistvattestingcentersinbelgiumgermanyspainandtheukusingthecobastvmgmolecularassay
AT arcenasrodney prevalenceofmycoplasmagenitaliummgandtrichomonasvaginalistvattestingcentersinbelgiumgermanyspainandtheukusingthecobastvmgmolecularassay
AT hansraavneet prevalenceofmycoplasmagenitaliummgandtrichomonasvaginalistvattestingcentersinbelgiumgermanyspainandtheukusingthecobastvmgmolecularassay
AT njoyamerlin prevalenceofmycoplasmagenitaliummgandtrichomonasvaginalistvattestingcentersinbelgiumgermanyspainandtheukusingthecobastvmgmolecularassay
AT garciafederico prevalenceofmycoplasmagenitaliummgandtrichomonasvaginalistvattestingcentersinbelgiumgermanyspainandtheukusingthecobastvmgmolecularassay